• Candel Therapeutics disclosed extended follow-up results from its pivotal Phase 3 trial of CAN-2409 in intermediate- to high-risk localized prostate cancer, presented at AUA 2026.
• Prolonged follow-up continued to show fewer prostate cancer recurrences versus placebo when CAN-2409 was added to standard radiotherapy.
• Secondary readouts also favored CAN-2409, pointing to longer periods before disease progression and reduced spread, though most measures remained exploratory at this stage.
• Candel plans to submit a Biologics License Application to US FDA in Q4 2026.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Candel Therapeutics Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202605151605PRIMZONEFULLFEED9721332) on May 15, 2026, and is solely responsible for the information contained therein.